Abstract:Background Psoriasis severity has traditionally been categorized as mild, moderate, and severe. Commonly, cut-offs for severe disease require a body surface area (BSA) involvement of ≥10% or a Psoriasis Area Severity Index (PASI) > 10. However, clinical experience challenges these traditional measures and requirements, as patients with less extensive psoriasis may have disease that severely impacts quality of life. Objective The objective of the present study was to further explore the extent of patient burden when psoriasis affects special locations. Methods A total of 69,190 individuals living in the U.S were invited to participate in a patient advocacy survey by telephone and or web interviews over the course of 3 years (2019-2021). The survey instrument consisted of validated patient-reported outcome measures, measuring disease-specific quality of life (Dermatology Life Quality Index, DLQI), depression (Patient Health Questionnaire (PHQ)-2 and (PHQ)-9), and the ability to participate in social roles and activities (PROMIS Ability to Participate in Social Roles and Activities (SF-4a). Chi-square tests were performed to explore association between psoriasis involvement on special locations and patient outcomes and multivariate logistic regression models were then constructed, to assess impact of having psoriasis on special locations patient outcomes, controlling for potential confounding factors. Results A total of 4129 individuals completed the survey. 3594 (84.4%) of patients surveyed reported psoriasis involving special areas of the bodysuch as the scalp, face, hands, feet, or genitalia. Involvement of special areas is associated with worse quality of life and depression. 35-71% of patients with 10% or less total BSA involvement experienced a moderate-to-extremely large effect on these life function domains. When adjusting for age, sex, and body surface area, psoriasis involvement of a special location was associated with poorer patient reported outcomes, including a 46% less likelihood of reporting their skin disease as having “no or only a small effect on QoL,” a 30% less likelihood of having a “normal l ability to participate in social roles and activities,” and a 126% higher likelihood of f having depression. Conclusion Real-world data presented here demonstrate that psoriasis involving special areas is associated with adverse life consequences, including poor quality of life and depression.

Relationship Between Patient Acceptable Symptom State and Disease Scores in Psoriasis

Prevalence and Clinical Characteristics of Pruritus in Patients with Psoriasis

Reliability, validity, and the ability to detect change of the Psoriasis Symptom Scale (PSS) in patients with plaque psoriasis

Development of Psoriasis Assessment Tools Among Patients in the CorEvitas Psoriasis Registry

Validation of a Simple Measure of Psoriasis Severity Based on a Longitudinal Study of Chinese Patients.

Stability of the patient acceptable symptomatic state over time in outcome criteria in ankylosing spondylitis

Health Utility and Its Affacting Factors for Patients with Psoriasis in China

Visit Adherence of Mild to Moderate Psoriasis Patients: A Mobile-Based Randomized Study.

Psoriatic Foot Involvement is the Most Significant Contributor to the Inconsistency Between PASI and DLQI: A Retrospective Study from China.

Correlation between Dermatology Life Quality Index and Psoriasis Area and Severity Index in Patients with Psoriasis: A Cross-sectional Global Healthcare Study on Psoriasis

Life quality among psoriasis patients based on Dermatology Life Quality Index evaluation and its association with psoriasis severity in China: a cross-sectional study

Determinants of social anxiety and social avoidance in psoriasis outpatients

Psoriasis Involving Special Areas is Associated with Worse Quality of Life, Depression, and Limitations in the Ability to Participate in Social Roles and Activities

Lesion Area Reduction and the Amelioration of Anxiety and Depression States in Psoriasis Patients: A Prospective Clinical Study.

Evaluation of the inflammatory parameters as potential biomarkers of systemic inflammation extent and the disease severity in psoriasis patients

Prevalence and Impact of Unacceptable Symptom State among Patients with Psoriatic Arthritis: Results from the National Psoriasis Foundation's 2019 Annual Survey

Reaction to Disease and Coping Strategies in Stressful Situations among Psoriasis Patients: Cross-Sectional Study

Knowledge, attitude, and practice of psoriasis patients toward their diseases: a web-based, cross-sectional study

Measurement Properties of the Patient Global Assessment Numerical Rating Scale in Moderate-to-severe Psoriasis.

Impact of disease, musculoskeletal symptoms and disease control in the CorEvitas Psoriasis Registry

Comparison of quality of life, depression and fatigue in patients with psoriasis and psoriatic arthritis